New immunotherapy combo shows promise for advanced liver cancer

NCT ID NCT05883644

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tumors. The goal is to control the disease and improve survival, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Shreveport, Louisiana, 71103, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

Bobigny, 93000, France
Research Site

Clichy, 92110, France
Research Site

Créteil, 94010, France
Research Site

Marseille, 13005, France
Research Site

Rennes, 35000, France
Research Site

Berlin, D-13353, Germany
Research Site

Cologne, 50937, Germany
Research Site

Frankfurt, 60488, Germany
Research Site

Lübeck, 23538, Germany
Research Site

Hong Kong, 0000, Hong Kong
Research Site

Shatin, 00000, Hong Kong
Research Site

Milan, 20132, Italy
Research Site

Naples, 80147, Italy
Research Site

Padova, 35128, Italy
Research Site

Pisa, 56126, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Turin, 10128, Italy
Research Site

Kanazawa, 920-8641, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Matsuyama, 790-0024, Japan
Research Site

Musashino-shi, 180-8610, Japan
Research Site

Osakasayama-shi, 589-8511, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

Singapore, 119228, Singapore
Research Site

Singapore, 169610, Singapore
Research Site

Singapore, 308433, Singapore
Research Site

Gyeonggi-do, 13620, South Korea
Research Site

Seongnam-si, 13496, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 8035, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28040, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Hanoi, 100000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.